A Phase 1 clinical trial recently published in the Journal of Clinical Pharmacology in Drug Development found that the oral CBD compound PTL101 – a new formulation of highly purified CBD in seamless gelatin matrix pellets – helped treat spasticity in those suffering from MS.
Researchers with Phytotech Therapeutics sought to determine how PTL101 is absorbed, distributed, and expelled throughout the body, as well as whether a 10 or 100 mg dose is more effective. They also compared the effects to Sativex, a CBD-based oromucosal spray approved for use in hospitals in Israel and Europe.
The trial took place in Israel and used GelpellR technology, which creates organic PTL101 beads.
“PTL101 is a pharmaceutical-grade, user-friendly oral formulation that demonstrated safe and efficient delivery of CBD and therefore could be an attractive candidate for therapeutic indications,” reads the study.
Phase 2 of the study is expected to finish sometime in December.
h/t Pot Network